ORIC Pharmaceuticals develops cancer drug candidates in South San Francisco, led by rinzimetostat for prostate cancer and enozertinib for lung cancer. It last closed at $7.36 on Nov 20, down 4.42% on the day. The next earnings report for ORIC is expected around Mon, Feb 22, 2027, after the close. For the quarter ended Sep 2026, ORIC reported EPS of -$0.44. Over its last 8 reports the stock moved an average of 8.1% the session after earnings. Over the last 12 months ORIC insiders bought $0 of stock on the open market and sold $3.0M, according to SEC Form 4 filings.
AI Auto Pilots
Is ORIC in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold ORIC.
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha callBullish64%
OPTIONS
+2
DARK POOL
+1
HISTORY
0
TECHNICAL
+1
StreetAlpha's call on ORICStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in
ORIC · as of the Nov 20 close · updated each morning
Downtrend, nearing oversold
The stock is 17% below its 20 day and 51% below its 50 day average. It is 48% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 32), near oversold. The nearest support is the swing low (Jun 3) at $7.32, and the nearest resistance the Pivot at $7.55.
Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityHigh, 10.1%/day
Key levels
$14.6852 week high+99.5%
$11.71100 day average+59.1%
$11.0850 day average+50.5%
$10.92200 day average+48.4%
$8.6320 day average+17.3%
$8.50Swing high (Jun 10)+15.5%
$7.82Pivot R1+6.3%
$7.55Pivot+2.6%
$7.36Last close
$7.32Swing low (Jun 3)−0.5%
$7.2352 week low−1.8%
$7.09Pivot S1−3.7%
Indicators
RSI (14)
31.63
Weak, oversold below 30
Neutral
MACD
-1.05
Below its signal line
Bearish
Stochastic
5.4
Near the bottom of its range
Oversold
ADX (14)
31.4
Trending down
Williams %R
-97.0
Oversold below −80, overbought above −20
Oversold
CCI (20)
-134.7
Oversold below −100, overbought above 100
Oversold
Rate of change
−16.6%
Change over 10 sessions
Bearish
ATR (14)
$0.74
Typical daily range, 10.1% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Pullback inside a longer uptrend, nearing oversold
Short trendBearish
Long trendBullish
MomentumWeak
StretchNear oversold
VolatilityNormal, 24.0%/day
Key levels
$14.6852 week high+99.5%
$11.71100 day average+59.1%
$11.0850 day average+50.5%
$10.92200 day average+48.4%
$8.6320 day average+17.3%
$8.50Swing high (Jun 10)+15.5%
$7.82Pivot R1+6.3%
$7.55Pivot+2.6%
$7.36Last close
$7.32Swing low (Jun 3)−0.5%
$7.2352 week low−1.8%
$7.09Pivot S1−3.7%
Indicators
RSI (14)
35.37
Weak, oversold below 30
Neutral
MACD
-0.50
Below its signal line
Bearish
Stochastic
3.4
Near the bottom of its range
Oversold
ADX (14)
19.9
No clear trend
Williams %R
-98.8
Oversold below −80, overbought above −20
Oversold
CCI (20)
-203.2
Oversold below −100, overbought above 100
Oversold
Rate of change
−38.9%
Change over 10 sessions
Bearish
ATR (14)
$1.77
Typical daily range, 24.0% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for ORIC
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how ORIC did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.
November seasonalityHow ORIC usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.
Whale options flow for ORICHow many large options trades hit ORIC, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in
No whale options trades in ORIC in the last 90 days.
From SEC Form 4 filings by ORIC's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.
AI Auto Pilots
Paper trading
StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ORIC is in one of them and how their past ORIC trades turned out.
ORIC Pharmaceuticals is a biopharmaceutical company based in South San Francisco, California, that develops cancer treatments designed to counter drug resistance. Its two lead candidates are rinzimetostat, which is being studied in advanced prostate cancer, and enozertinib, which is being studied in lung cancer with certain EGFR gene mutations. Neither candidate has been approved for sale yet.